Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Pomalidomide + Dexamethasone ± Carfilzomib in RRMM (SCOPE)
NCT04764942Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- May 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Mayo Clinic. Started May 2021; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04764942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04764942.